Physician profile
Julia E Mcguinness
NPI 1003201435
$11,121.58
in general payments reported to CMS, 2019-2025
16 companies · $4,255 in 2025
The $4,255 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,252 · 2023: $3,227 · 2024: $2,388 · 2025: $4,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,140 · Food and Beverage: $1,404 · Travel and Lodging: $975 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,140.00 |
| Food and Beverage | $1,403.98 |
| Travel and Lodging | $975.17 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,883.52 | 2023-2025 | |
| Gilead Sciences, INC. | $2,700.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $2,021.95 | 2024-2025 | |
| Seagen INC. | $1,225.00 | 2022 | |
| Daiichi Sankyo INC. | $865.80 | 2022-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $154.44 | 2025 | Itovebi |
| Tactile Systems Technology INC | $112.70 | 2023 | Flexitouch Plus, Entre Plus |
| Ge Healthcare | $109.12 | 2023 | |
| Genentech, INC. | $49.05 | 2025 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Mcguinness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.